A Patient Driven Multi-Stage Pipeline
| Candidate | Target Indications | Development Phase | Partner | ||||
|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Commercial | |||
Deramiocel (CAP-1002)(allogeneic CDCs) |
Duchenne muscular dystrophy |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Commercial Phase not started
|
Nippon Shinyaku |
Exosome-Based Vaccine(Multivalent design) |
Infectious diseases (SARS-CoV-2) |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Commercial Phase not started
|
National Institute of Allergy |
Engineered Exosomes(RNA, protein and small molecule delivery) |
Evaluating |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Commercial Phase not started
|
|
CAP-2003(allogeneic CDC-exosomes) |
Duchenne muscular dystrophy |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Commercial Phase not started
|
|
Cell Therapy
Exosome Platform